Variables
|
Total
|
Cytoplasm
|
Nucleus
|
Cytoplasm and nucleus
|
---|
|
n
|
Low
|
High
|
(%)
|
p
1
|
Low
|
High
|
(%)
|
p
1
|
Low
|
High
|
(%)
|
p
1
|
---|
Age
| | | | |
0.21
| | | |
0.96
| | | |
0.06
|
25–69
|
121
|
39
|
82
|
(68)
| |
49
|
72
|
(60)
| |
38
|
83
|
(69)
| |
70–84
|
147
|
34
|
113
|
(77)
| |
62
|
85
|
(58)
| |
28
|
119
|
(81)
| |
85+
|
34
|
11
|
23
|
(68)
| |
14
|
20
|
(59)
| |
10
|
24
|
(71)
| |
FIGO
| | | | |
0.26
| | | |
0.49
| | | |
0.08
|
Ia
|
11
|
2
|
9
|
(82)
| |
4
|
7
|
(64)
| |
2
|
9
|
(82)
| |
Ib
|
37
|
16
|
21
|
(57)
| |
19
|
18
|
(49)
| |
16
|
21
|
(57)
| |
II
|
110
|
28
|
82
|
(75)
| |
43
|
67
|
(61)
| |
22
|
88
|
(80)
| |
III
|
121
|
32
|
89
|
(74)
| |
46
|
75
|
(62)
| |
30
|
91
|
(75)
| |
IV
|
19
|
5
|
14
|
(74)
| |
10
|
9
|
(47)
| |
5
|
14
|
(74)
| |
Not available
|
4
| | | | | | | | | | | | |
Lymph node metastasis
| | | | |
0.42
| | | |
0.97
| | | |
0.54
|
None
|
137
|
41
|
96
|
(70)
| |
55
|
82
|
(60)
| |
36
|
101
|
(74)
| |
Unilateral
|
76
|
18
|
58
|
(76)
| |
31
|
45
|
(59)
| |
17
|
59
|
(78)
| |
Bilateral
|
34
|
12
|
22
|
(65)
| |
13
|
21
|
(62)
| |
11
|
23
|
(68)
| |
Not available
|
55
| | | | | | | | | | | | |
Tumour diameter (cm)
| | | | |
0.001
| | | |
0.002
| | | |
0.001
|
0.3–2.5
|
92
|
34
|
58
|
(63)
| |
50
|
42
|
(46)
| |
33
|
59
|
(64)
| |
2.6–4.0
|
94
|
30
|
64
|
(68)
| |
35
|
59
|
(63)
| |
25
|
69
|
(73)
| |
4.1–20.0
|
100
|
14
|
86
|
(86)
| |
30
|
70
|
(70)
| |
12
|
88
|
(88)
| |
Not available
|
16
| | | | | | | | | | | | |
Tumor differentiation
| | | | |
0.09
| | | |
0.10
| | | |
0.08
|
Well
|
76
|
27
|
49
|
(65)
| |
39
|
37
|
(49)
| |
25
|
51
|
(67)
| |
Moderate
|
154
|
43
|
111
|
(72)
| |
61
|
93
|
(60)
| |
39
|
115
|
(75)
| |
Poor
|
72
|
14
|
58
|
(81)
| |
25
|
47
|
(65)
| |
12
|
60
|
(83)
| |
Depth of invasion (mm)
| | | | |
0.01
| | | |
0.001
| | | |
0.007
|
0.0–4.0
|
80
|
32
|
48
|
(60)
| |
45
|
35
|
(44)
| |
30
|
50
|
(63)
| |
4.1–8.0
|
99
|
24
|
75
|
(76)
| |
38
|
61
|
(62)
| |
21
|
78
|
(79)
| |
8.1–40.0
|
112
|
24
|
88
|
(79)
| |
34
|
78
|
(70)
| |
21
|
91
|
(81)
| |
Not available
|
11
| | | | | | | | | | | | |
Infiltration of vessel
| | | | |
0.33
| | | |
0.50
| | | |
0.41
|
No
|
233
|
67
|
166
|
(71)
| |
99
|
134
|
(58)
| |
61
|
172
|
(74)
| |
Yes
|
66
|
15
|
51
|
(77)
| |
25
|
41
|
(62)
| |
14
|
52
|
(79)
| |
Not available
|
3
| | | | | | | | | | | | |
p142
| | | | |
1.00
| | | |
1.00
| | | |
0.88
|
Low (-)
|
135
|
98
|
37
|
(27)
| |
46
|
89
|
(66)
| |
84
|
51
|
(38)
| |
High (+)
|
77
|
56
|
21
|
(27)
| |
26
|
51
|
(66)
| |
49
|
28
|
(36)
| |
Not available
|
100
| | | | | | | | | | | | |
p162
| | | | |
0.63
| | | |
0.88
| | | |
0.15
|
Low (< 5%)
|
148
|
40
|
108
|
(73)
| |
51
|
97
|
(66)
| |
37
|
111
|
(75)
| |
High (≥ 5%)
|
63
|
15
|
48
|
(76)
| |
21
|
42
|
(67)
| |
10
|
53
|
(84)
| |
Not available
|
91
| | | | | | | | | | | | |
p212
| | | | |
0.17
| | | |
0.87
| | | |
0.10
|
Low (-)
|
122
|
36
|
86
|
(71)
| |
42
|
80
|
(66)
| |
32
|
90
|
(74)
| |
High (+)
|
90
|
19
|
71
|
(79)
| |
30
|
60
|
(67)
| |
15
|
75
|
(84)
| |
Not available
|
90
| | | | | | | | | | | | |
p272
| | | | |
0.18
| | | |
0.56
| | | |
0.19
|
Low (< 50%)
|
164
|
39
|
125
|
(76)
| |
54
|
110
|
(67)
| |
33
|
131
|
(80)
| |
High (≥ 50%)
|
48
|
16
|
32
|
(67)
| |
18
|
30
|
(63)
| |
14
|
34
|
(71)
| |
Not available
|
90
| | | | | | | | | | | | |
p532
| | | | |
0.70
| | | |
0.12
| | | |
0.93
|
Low (< 5%)
|
93
|
25
|
68
|
(73)
| |
26
|
67
|
(72)
| |
20
|
73
|
(79)
| |
High (≥ 5%)
|
118
|
29
|
89
|
(75)
| |
45
|
73
|
(62)
| |
26
|
92
|
(78)
| |
Not available
|
91
| | | | | | | | | | | | |
Cyclin A2
| | | | |
0.68
| | | |
0.09
| | | |
0.59
|
Low (< 5%)
|
61
|
17
|
44
|
(72)
| |
26
|
35
|
(57)
| |
15
|
46
|
(75)
| |
High (≥ 5%)
|
151
|
38
|
113
|
(75)
| |
46
|
105
|
(70)
| |
32
|
119
|
(79)
| |
Not available
|
90
| | | | | | | | | | | | |
Cyclin D12
| | | | |
0.87
| | | |
0.75
| | | |
0.83
|
Low (-)
|
156
|
40
|
116
|
(74)
| |
52
|
104
|
(67)
| |
34
|
122
|
(78)
| |
High (+)
|
56
|
15
|
41
|
(73)
| |
20
|
36
|
(64)
| |
13
|
43
|
(77)
| |
Not available
|
90
| | | | | | | | | | | | |
Cyclin D32
| | | | |
0.25
| | | |
0.76
| | | |
0.69
|
Low (< 50%)
|
153
|
43
|
110
|
(72)
| |
51
|
102
|
(67)
| |
35
|
118
|
(77)
| |
High (≥ 50%)
|
59
|
12
|
47
|
(80)
| |
21
|
38
|
(64)
| |
12
|
47
|
(80)
| |
Not available
|
90
| | | | | | | | | | | | |
Cyclin E2
| | | | |
0.72
| | | |
0.64
| | | |
0.32
|
Low (< 50%)
|
173
|
44
|
129
|
(75)
| |
60
|
113
|
(65)
| |
36
|
137
|
(79)
| |
High (≥ 50%)
|
39
|
11
|
28
|
(72)
| |
12
|
27
|
(69)
| |
11
|
28
|
(72)
| |
Not available
|
90
| | | | | | | | | | | | |
HPV2
| | | | |
0.87
| | | |
0.47
| | | |
0.98
|
Low (-)
|
168
|
44
|
124
|
(74)
| |
57
|
111
|
(66)
| |
39
|
129
|
(77)
| |
High (+)
|
44
|
11
|
33
|
(75)
| |
15
|
29
|
(66)
| |
8
|
36
|
(82)
| |
Not available
|
90
| | | | | | | | | | | | |
-
1 Pearson chi-square 2 In previous reports, p53, p16, p21, p27, p14, cyclin A, cyclin D1, cyclin D3, cyclin E and HPV have been studied [28–31].